Login to Your Account

Financings Roundup

Antibody Firm KaloBios Prices $70M IPO in Lukewarm Debut

By Jennifer Boggs
Managing Editor

Friday, February 1, 2013
In the second biotech initial public offering (IPO) to price this week, antibody drug developer KaloBios Pharmaceuticals Inc. priced a slightly upsized offering of 8.75 million shares at $8 apiece for gross proceeds of $70 million. Like Stemline Therapeutics Inc., which priced an IPO Tuesday, KaloBios came in at the low end of its expected pricing range.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription